CLC
RDY icon

Charles-Lim Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

Charles-Lim Capital’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-611,990
Closed -$4.96M – 4
2019
Q1 		$4.96M Sell
611,990
-1,447,025
-70% -$11M 1.02% 4
2018
Q4 		$15.5M Buy
+2,059,015
New +$14.5M 4.56% 4

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Charles-Lim Capital's RDY Position: Q2 2019 in Review

Charles-Lim Capital sold out of Dr. Reddy's Laboratories (RDY) in Q2 2019, closing a stake of 611,990 shares — an estimated $4.96M sold.

Charles-Lim Capital first reported a position in RDY in Q4 2018 and held it in 2 quarters. The position peaked at $15.5M in Q4 2018. 150 funds tracked by Wall St. Rank hold RDY as of Q2 2019.

  • Charles-Lim Capital reported no remaining Dr. Reddy's Laboratories position as of Q2 2019 after selling out during the quarter.
  • Charles-Lim Capital sold 611,990 Dr. Reddy's Laboratories shares in Q2 2019, an estimated $4.96M.
  • Charles-Lim Capital first reported a position in Dr. Reddy's Laboratories in Q4 2018 and held it in 2 quarters.
  • Charles-Lim Capital's Dr. Reddy's Laboratories position peaked at $15.5M in Q4 2018.
  • 150 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2019.

Based on Charles-Lim Capital's 13F filing for Q2 2019, filed 14 Aug 2019.